GlaxoSmithKline PLC is building up its respiratory franchise with the Nov. 4 approval of Nucala (mepolizumab) as an add-on maintenance treatment of patients with severe asthma aged 12 years and older who have an eosinophilic phenotype.
The targeted use is in line with the recommendations of FDA’s Pulmonary-Allergy Drugs Advisory Committee